Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01994382 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 260
- Enrollment target
NCT01994382 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 260 participants.
The verdict
NCT01994382, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 260 participants
- Enrollment target
Study Summary
This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin lymphoma.
Interventions
- BIOLOGICAL Rituximab
- DRUG Cerdulatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2013-08-30 |
| Est. Completion | 2020-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01994382
The ClinicalTrials.gov registry entry for NCT01994382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT01994382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01994382 about?
NCT01994382 is a clinical study titled "Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL". This study will identify the highest dose, and assess the safety, of cerdulatinib (PRT062070) that may be given in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or non-hodgkin lymphoma.
What is the current status of trial NCT01994382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 260 participants. The study started on 2013-08-30. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT01994382?
The interventions under investigation include: Rituximab (BIOLOGICAL), Cerdulatinib (DRUG).
Who is sponsoring clinical trial NCT01994382?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.